A Continuation Protocol for Deucravacitinib in Patients With Patients With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Participants must have completed Study IM011074 or Study IM011132 through the protocol-required treatment period.
• Participants must be, based on the physician's medical judgement, likely to receive benefit from receiving treatment with deucravacitinib.
• Participants must have received IP within 60 days of enrollment. Exceptions may be granted based upon consultation with BMS.
Locations
United States
Connecticut
Local Institution - 0001
WITHDRAWN
Farmington
New York
New York University School Of Medicine
RECRUITING
New York
Tennessee
Local Institution - 0003
WITHDRAWN
Jackson
Contact Information
Primary
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain the NCT# and Site#
Time Frame
Start Date: 2025-08-29
Estimated Completion Date: 2026-12-01
Participants
Target number of participants: 35
Treatments
Experimental: Administration of BMS-986165
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb